Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Focus Turns To Label After Panel Backs Acadia's Nuplazid

This article was originally published in Scrip

Executive Summary

If the FDA takes its outside experts' advice, Acadia Pharmaceuticals Inc. could finally be on its way to having a billion dollar drug on the US market: Nuplazid (pimavanserin), a selective inverse agonist of the 5-hydroxytryptamine 2A (5-HT2A) receptor, which the biotech is seeking as a treatment for psychosis associated with Parkinson's disease (PDP).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel